Skip to main content
. 2024 Mar 19;19:127. doi: 10.1186/s13023-024-03129-6

Table 2.

Participant demographics for ALD cross-sectional study

Cross-sectional study participants, n 109
Sex, n (%)
 Male 47 (43.1)
 Female 62 (56.9)
Age in years
 Mean ± 1 SD 51 ± 17
 Range 18–83
Race, n (%)
 Asian 3 (2.8)
 Black/African American 1 (0.9)
 White 98 (89.9)
 Other 7 (6.4)
Hispanic or Latino, n (%)
 Yes 15 (13.8)
 No 94 (86.2)
Country, n (%) (16 total countries represented)
 United States 54 (49.5)
 Canada 5 (4.6)
 Australia 10 (9.7)
 United Kingdom 16 (14.7)
 France 2 (1.8)
 Argentina 7 (6.4)
 Bolivia 2 (1.8)
 Chile 1 (0.9)
 India 1 (0.9)
 Iran 1 (0.9)
 Ireland 3 (2.8)
 Mexico 1 (0.9)
 New Zealand 3 (2.8)
 Poland 1 (0.9)
 South Korea 1 (0.9)
 Sweden 1 (0.9)
U.S. states represented, n 21
Canadian provinces represented (Ontario), n 1
Employment status, n (%)
 Employed full-time 29 (26.6)
 Employed part-time 9 (8.3)
 On disability 16 (14.7)
 Not working/not on disability 8 (7.3)
 Retired 30 (27.5)
 Student 6 (5.5)
 Stay-at-home parent 1 (0.9)
 Self-employed 7 (6.4)
 Other 3 (2.8)
Has ALD impacted your employment status or choice?, n (%)
 Yes 60 (55.1)
 No 40 (36.7)
 I don't know 8 (7.3)
 Prefer not to answer 1 (0.9)
Highest level of education, n (%)
 Grade school 2 (1.8)
 High school 29 (26.6)
 Technical degree 19 (17.5)
 College 33 (30.3)
 Master's or Doctorate 24 (22.0)
 None 2 (1.8)
Has ALD prevented you from pursuing additional education?, n (%)
 Yes 18 (16.5)
 No 87 (79.8)
 I don't know 4 (3.7)
Marital status, n (%)
 Married 61 (56.0)
 Single 26 (23.9)
 Widowed 3 (2.7)
 Divorced 13 (12.0)
 Separated 3 (2.7)
 Registered partnership 3 (2.7)
Has ALD impacted your marital status or decision to pursue relationships?, n (%)
 Yes 35 (32.1)
 No 70 (64.2)
 I don't know 4 (3.7)
Diagnosed with ALD?, n (%)
 Yes 59 (54.1)
 No 43 (39.5)
 I don't know 7 (6.4)
Diagnosed with AMN?, n (%)
 Yes 71 (65.1)
 No 27 (24.8)
 I don't know 11 (10.1)
Diagnosed with cerebral form of ALD?, n (%)
 Yes 18 (16.5)
 No 81 (74.3)
 I don't know 10 (9.2)
Diagnosed with Addison's disease?, n (%)
 Yes 35 (32.1)
 No 71 (65.1)
 I don't know 3 (2.8)
Ever been in adrenal crisis?, n (%)
 Yes 22 (20.2)
 No 82 (75.2)
 I don't know 5 (4.6)
Years since diagnosis
 Mean ± 1 SD 16 ± 11
 Range 1–40
Years since first noticed symptoms
 Mean ± 1 SD 15 ± 11
 Range 0–50
Ever misdiagnosed?, n (%)
 Yes 38 (34.9)
 No 68 (62.4)
 I don't know 3 (2.7)
Ambulation, n (%)
 Walk independently without assistance 50 (45.9)
 Primarily use a cane or crutches 34 (31.2)
 Primarily use a walker 10 (9.2)
 Use a wheelchair or motorized scooter sometimes and walk sometimes 7 (6.4)
 Primarily use a wheelchair or motorized scooter 8 (7.3)
Hours of home health aide per week, n (%)
 None 75 (68.8)
 1–5 h 15 (13.8)
 6–10 h 6 (5.5)
 16–20 h 3 (2.7)
 Greater than 20 h 10 (9.2)
Speech, n (%)
 Talk clearly and have no changes in speech 89 (81.7)
 Some speech changes 17 (15.6)
 Impaired speech, and people occasionally ask to repeat words or phrases 2 (1.8)
 Impaired speech that is often not understood by others 1 (0.9)
Positive genetic test for ABCD1 gene mutation?, n (%)
 Yes 89 (81.6)
 No 5 (4.6)
 No genetic testing 11 (10.1)
 I don't know 4 (3.7)
Functional ability, n (%)
 No symptoms 4 (3.7)
 No significant disability 26 (23.8)
 Slight disability 32 (29.4)
 Moderate disability 29 (26.6)
 Moderately severe disability 18 (16.5)
Ever received bone marrow or stem cell transplant?, n (%)
 Yes 5 (4.6)
 No 104 (95.4)
Current treatments, n (%)a
 Hormone replacement, steroid medications, or corticosteroids 34 (31.2)
 High dose antioxidants (OTC) 4 (3.7)
Lorenzo's oil 2 (1.8)
 Spasticity-reducing medications (Baclofen, Tazanidine, Botox, etc.) 33 (30.3)
 Neuropathic pain medications or anti-epileptic medications (Neurontin e.g. Gabapentin) 32 (29.4)
 Medications for overactive bladder or bowel 21 (19.3)
 Cannabidiol (CBD) 15 (13.8)
 Anti-depressants or anti-anxiety medications 24 (22.0)
 Physical therapy 32 (29.4)
 None 20 (18.4)

Multiple-choice options that were not selected by any participant have been omitted for conciseness

Percents have been normalized for missing responses

aPercents may not add up to 100% because some individuals receive multiple treatments